@article{oai:nagasaki-u.repo.nii.ac.jp:00000797,
 author = {Hashimoto, Miki and Itonaga, Hidehiro and Nannya, Yasuhito and Taniguchi, Hirokazu and Fukuda, Yuichi and Furumoto, Takafumi and Fujioka, Machiko and Kasai, Sachie and Taguchi, Masataka and Taniguchi, Hiroaki and Sato, Shinya and Sawayama, Yasushi and Atogami, Sunao and Iwasaki, Keisuke and Hata, Tomoko and Soda, Hiroshi and Moriuchi, Yukiyoshi and Nakata, Koh and Ogawa, Seishi and Miyazaki, Yasushi},
 issue = {8},
 journal = {Internal Medicine},
 month = {Apr},
 note = {Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment., Internal Medicine, 59(8), pp.1081-1086; 2020},
 pages = {1081--1086},
 title = {Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome},
 volume = {59},
 year = {2020}
}